Inferra AIResearch Tools

Inferra AI / Company / ACHV

Achieve Life Sciences

ACHV · Health Care

Last earnings Aug 11, 2026

AI analysis

Q2 2026 · reported Aug 11, 2026

Based on: Earnings release + parent 8-K — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

• Announced the transition of finished drug product manufacturing of cytisinicline to U.S.-based Adare Pharma Solutions (Adare)

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

(Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the second quarter of 2026 and provided business updates.

SEC original ↗Achieve Life Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2026

is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence.

SEC original ↗Achieve Life Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2026

FDA has awarded the Commissioner’s National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation to address this critical need.

SEC original ↗Achieve Life Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Achieve Contact Nicole Jones VP, Strategic Communications and Stakeholder Relations ir@achievelifesciences.

SEC original ↗Achieve Life Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Risks & headwinds

These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

SEC original ↗Achieve Life Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

26 documents

Earnings releases

4 documents

Presentations

0 documents

No presentations for Achieve Life Sciences are held in this edition of the library.

Transcripts

0 documents

No transcripts for Achieve Life Sciences are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.